Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics


Corcept Therapeutics Incorporated (CORT)

Today's Latest Price: $17.18 USD

0.09 (0.53%)

Updated Jul 2 4:00pm

Add CORT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

CORT Stock Summary

  • The ratio of debt to operating expenses for Corcept Therapeutics Inc is higher than it is for about merely 5.97% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.1 for Corcept Therapeutics Inc; that's greater than it is for merely 9.1% of US stocks.
  • With a year-over-year growth in debt of 104.6%, Corcept Therapeutics Inc's debt growth rate surpasses 88.01% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Corcept Therapeutics Inc are FORM, CHRS, QLYS, FIT, and LSCC.
  • Visit CORT's SEC page to see the company's official filings. To visit the company's web site, go to www.corcept.com.
CORT Daily Price Range
CORT 52-Week Price Range

CORT Stock Price Chart Technical Analysis Charts


CORT Price/Volume Stats

Current price $17.18 52-week high $18.52
Prev. close $17.09 52-week low $9.70
Day low $16.84 Volume 806,142
Day high $17.49 Avg. volume 1,048,585
50-day MA $14.81 Dividend yield N/A
200-day MA $13.52 Market Cap 1.97B

Corcept Therapeutics Incorporated (CORT) Company Bio


Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.

CORT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$17.18$982.225799%

We started the process of determining a valid price forecast for Corcept Therapeutics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Corcept Therapeutics Inc ranked in the 95th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for CORT, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 100. Its equity weight surpasses that of 93.96% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.41% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Corcept Therapeutics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -23.96. This coverage rate is greater than that of only 4.96% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%5684%
1%5741%
2%5799%
3%5857%
4%5915%
5%5973%

THC, RDY, DVCR, FVE, and INBP can be thought of as valuation peers to CORT, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


CORT Latest News Stream


Event/TimeNews Detail
Loading, please wait...

CORT Latest Social Stream


Loading social stream, please wait...

View Full CORT Social Stream

Latest CORT News From Around the Web

Below are the latest news stories about Corcept Therapeutics Inc that investors may wish to consider to help them evaluate CORT as an investment opportunity.

Corcept Therapeutics initiates late-study for Relacorilant doublet therapy in pancreatic cancer

Corcept Therapeutics ([[CORT]] +1.2%) enrolls first patient in RELIANT, a Phase 3 trial of relacorilant in combination with nab-paclitaxel (Celgene’s Abraxane) in patients with metastatic pancreatic cancer.The company plans to enroll 80 patients, with an interim analysis of data from the first 40 patients.The primary endpoint is objective response rate, with...

Seeking Alpha | July 1, 2020

Corcept Begins Enrollment in Phase III Pancreatic Cancer Study

Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

Yahoo | July 1, 2020

Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in RELIANT, an open-label, Phase 3 trial of relacorilant in combination with nab-paclitaxel (Celgene’s medication, Abraxane®) in patients with metastatic pancreatic cancer. “Metastatic pancreatic cancer is an aggressive disease and there is an urgent need for effective therapies,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. RELIANT has a planned enrollment of 80 patients with metastatic pancreatic cancer, with an interim analysis of data from the first 40 patients.

Yahoo | June 30, 2020

The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dya...

Benzinga | June 24, 2020

Hedge Funds Standing By Corcept Therapeutics Incorporated (CORT)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | June 19, 2020

Read More 'CORT' Stories Here

CORT Price Returns

1-mo 18.48%
3-mo 47.47%
6-mo 41.63%
1-year 58.34%
3-year 43.65%
5-year 186.33%
YTD 41.98%
2019 -9.43%
2018 -26.02%
2017 148.76%
2016 45.78%
2015 66.00%

Continue Researching CORT

Here are a few links from around the web to help you further your research on Corcept Therapeutics Inc's stock as an investment opportunity:

Corcept Therapeutics Inc (CORT) Stock Price | Nasdaq
Corcept Therapeutics Inc (CORT) Stock Quote, History and News - Yahoo Finance
Corcept Therapeutics Inc (CORT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8523 seconds.